Tyrosine kinase inhibitors under investigation for the treatment of type II diabetes.
about
Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia.Novel members of quinoline compound family enhance insulin secretion in RIN-5AH beta cells and in rat pancreatic islet microtissue.Hyperglycaemia Induced by Novel Anticancer Agents: An Undesirable Complication or a Potential Therapeutic Opportunity?Cardiac Metabolic Deregulation Induced by the Tyrosine Kinase Receptor Inhibitor Sunitinib is rescued by Endothelin Receptor Antagonism
P2860
Tyrosine kinase inhibitors under investigation for the treatment of type II diabetes.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Tyrosine kinase inhibitors under investigation for the treatment of type II diabetes.
@en
type
label
Tyrosine kinase inhibitors under investigation for the treatment of type II diabetes.
@en
prefLabel
Tyrosine kinase inhibitors under investigation for the treatment of type II diabetes.
@en
P2860
P1476
Tyrosine kinase inhibitors under investigation for the treatment of type II diabetes.
@en
P2093
Rana Malek
Stephen N Davis
P2860
P304
P356
10.1517/13543784.2016.1142531
P407
P577
2016-01-14T00:00:00Z